TRAGIC ANNIVERSARY
Local authorities have delayed plans to open the site of the Union Carbide factory in Bhopal, India, that was responsible for a chemical leak that killed thousands of people 25 years ago this week. The state government of Madyha Pradesh said in early November that it would allow visitors to tour the plant in a bid to reassure people that it was now safe, amid protests from victims' groups (above). But the state's Gas Relief and Rehabilitation Minister Babulal Gaur said last week that the opening would be pushed back until after municipal elections in December, in line with rules forbidding major policy announcements in the run-up to the polls.
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Science stimulus: The Spanish government announced on 26 November which universities would benefit from the inaugural round of a €150-million (US$226-million) annual programme to bolster teaching and research in the country. See page 552 for more.
Radiation contamination:
The Nuclear Power Corporation of India has ordered a probe into what it believes to be sabotage that exposed 55 workers at its Kaiga plant in southwestern India to radiation last week. The workers were treated for poisoning after drinking from a water cooler contaminated with tritium -a radioactive isotope of hydrogen. Anil Kakodkar, chairman of the Atomic Energy • RESEARCH Record breaker: Just ten days after it was restarted, the Large Hadron Collider (LHC) has become the world's highestenergy particle accelerator. On 30 November, the giant machine, located at CERN, Europe's premier high-energy physics laboratory near Geneva, Switzerland, accelerated two recommended on 30 November that the widely used antiretroviral drug stavudine be phased out because of its "long-term, irreversible" side effects, which include nerve damage.
Commission of India, says the tritium may have been introduced into the cooler in a "malevolent act" by a disgruntled employee. A patient treated for pachyonychia congenita, a rare inherited skin disorder, saw some benefit after a series of RNAi injections into lesions on the sole of one foot. But the injections are too painful to treat the disease in the long term and many cancers, for example, cannot be treated by direct injection of an RNAi product.
RNAi RACE
Delivery is not the only problem facing RNAi. In May, a treatment for wet age-related macular degeneration was ditched by Allergan, a biotech company based in Irvine, California, after the therapy failed to improve patients' vision.
With concern growing over the side effects of RNAi-based treatments, firms must now "conclusively prove the mechanism of action of their products", says PharmaVision consultant Cheryl Barton. 
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